Industry News
Related Searches:
Filter by:
1861 - 1875 of 2391 results
October 3, 2007
Molecular Insight Pharmaceuticals, Inc. has completed the purchase of a commercial-scale radiopharmaceutical manufacturing facility in Denton, TX. The company purchased the facility from NeoRx Manufacturing Group, Inc., a subsidiary of Poniard Pharma…
Read More »
September 28, 2007
Novartis and the Massachusetts Institute of Technology (MIT) have entered a 10-year research collaboration with the goal of transforming the pharmaceutical production process.
The partnership, known as the Novartis-MIT Center for Continuous Manufa…
Read More »
September 27, 2007
PAREXEL International Corp. has completed the acquisition of Taiwan-based APEX International Clinical Research Co., Ltd. for approximately $51 million. The acquisition adds to PAREXEL's clinical research service offerings in the Asia-Pacific region,…
Read More »
September 27, 2007
SAFC will invest $29 million to expand its drug substance capabilities in high-potency biologics at the Sigma-Aldrich facility in Jerusalem, Israel. The site expansion will allow SAFC Pharma to provide process development and cGMP manufacturing for l…
Read More »
September 26, 2007
Baxter BioPharma Solutions recently completed the lyophilization capacity expansion at their cytotoxic contract manufacturing facility in Halle, Germany. The expansion increased their total cytotoxic lyophilization capacity to four dedicated lyophili…
Read More »
September 25, 2007
Bristol-Myers Squibb has signed a definitive agreement to acquire Adnexus Therapeutics for $430 million in cash. Adnexus has developed a new therapeutic class of biologics called Adnectins, which BMS plans to use to advance its biologics strategy in…
Read More »
September 25, 2007
GlaxoSmithKline has licensed MedImmune's reverse genetics technology for the development of new vaccine strains to produce non-live human influenza vaccines. Reverse genetics allows manufacturers to avoid working directly with the infectious, circula…
Read More »
September 25, 2007
DSM Venturing, the corporate unit of Royal DSM N.V., has made an equity investment in Upfront Chromatography, a developer of customized industrial protein chromatography processes. According to DSM, Upfront's downstream processing platform has the po…
Read More »
September 24, 2007
Verus Pharmaceuticals, Inc. sold its pediatric asthma development programs to AstraZeneca. This includes the North American rights to a Captisol enabled budesonide solution (controller medication), a short-acting beta agonist solution (rescue medicat…
Read More »
September 19, 2007
Genzyme Corp. broke ground on a $150 million expansion project at its Allston Landing manufacturing facility in Boston that will add space for manufacturing support functions and will create 90 jobs.
Commercial production at Allston Landing, which…
Read More »
September 17, 2007
AstraZeneca is planning to outsource all drug manufacturing activities within 10 years, according to a company statement. "Manufacturing for AstraZeneca is not a core activity," said David Smith, AstraZeneca's executive vice-president of op…
Read More »
September 14, 2007
Accenture and Bristol-Myers Squibb have launched a joint center for pharmacovigilance in Chennai, India. The new center will be operated by more than 140 Accenture employees and will undertake the processing and coding of adverse event data and the g…
Read More »
September 14, 2007
Gene Logic, Inc. has entered into a collaboration with the FDA regarding quality control methods and metrics for understanding disparate genomic data sent as part of regulatory submissions. The collaboration is part of the FDA's Critical Path Initiat…
Read More »
September 13, 2007
BioReliance Corp. has partnered with Gentronix to offer their GreenScreen HC in vitro assay as part of its genotoxicity screening services. GreenScreen HC, in conjunction with Ames II assays, allows pharmaceutical companies to test for genotoxic pote…
Read More »
September 12, 2007
Nabi Biopharmaceuticals will sell its Biologics unit to Biotest Pharmaceuticals Corp. for $185 million. The purchase includes the unit's products, including Nabi-HB (Hepatitis B Immune Globulin (Human)), and other plasma business assets, as well as N…
Read More »
1861 - 1875 of 2391 results
